Herceptin approved in Europe for stomach cancer

Thursday 28 January 2010

The European Commission has approved the Roche group’s breast cancer treatment, Herceptin (trastuzumab), for metastatic stomach cancer. The drug is to be used in combination with chemotherapy for patients with HER2-positive stomach cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.